Trevi Therapeutics to Participate in Upcoming September Conferences

NEW HAVEN, Conn., Aug. 28, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER)  for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in September.

2025 Wells Fargo Healthcare Conference
September 3 – 5, 2025, Everett, Massachusetts
Trevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, Pharm.D. CCO

Cantor Global Healthcare Conference 2025
September 3 – 5, 2025, New York, New York
Trevi Representatives: Jennifer Good, President and CEO, and James Cassella, Ph.D., CDO

Morgan Stanley 23^rd Annual Global Healthcare Conference
September 8 – 10, 2025, New York, New York
Fireside Chat: September 9, 4:05 p.m. ET
Trevi Representatives: Jennifer Good, President and CEO, and James Cassella, Ph.D., CDO
Register here to watch the live presentation.

H.C. Wainwright & Co. 27^th Annual Global Investment Conference
September 8 – 10, 2025, New York, New York
Trevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, Pharm.D. CCO

2025 Leerink Partners Biopharma Summit
September 17 – 19, 2025, Healdsburg, California
Trevi Representative: Jennifer Good, President and CEO

European Respiratory Society (ERS) Congress
September 27 – October 1, 2025, Amsterdam, Netherlands
Trevi Representatives: Jennifer Good, President and CEO, and James Cassella, Ph.D., CDO, Danine Summers, Vice President of Medical Affairs, and Abbey Nakano, Pharm.D., Associate Director of Medical Affairs

About Trevi Therapeutics, Inc.    
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials of patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.

Chronic cough is a highly prevalent condition, impacting up to 85% of patients with IPF. There are ~150,000 patients in the U.S. with IPF. The impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients.

Refractory chronic cough has no approved therapies in the U.S. and is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, and upper airway cough syndrome or post-nasal drip) and includes unexplained chronic cough. RCC affects ~2-3 million patients in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly debilitating disease and accompanied by a wide range of complications, ranging from urinary incontinence in females to sleep disruption and social embarrassment that causes significant social and economic burdens for patients and those around them.

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. 

For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn. 

Investor Contact 
Jonathan Carlson 
Trevi Therapeutics, Inc. 
(203) 654 3286 
[email protected]

Media Contact 
Rosalia Scampoli 
914-815-1465 
[email protected] 

View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-upcoming-september-conferences-302540243.html

SOURCE Trevi Therapeutics, Inc.